Skip to content

M2 — Alternative Splice Sites

Task. Recognize the alternative splice sites that the curated MANE annotation leaves out — defined as the set difference Ensembl ∖ MANE: competing donors/acceptors, minor isoforms, and tissue-specific sites. This is the regime where multimodal refinement produces its largest, most clear-cut win.

Bottom line: on alternative sites the base model is nearly blind — it recovers only ~17% of them. The promoted M2-S recovers ~90% at near-equal precision, lifting alternative-site PR-AUC from 0.911 to 0.990 and cutting false negatives by 88%.


Why M2 exists: the OOD problem

M1-S is trained on MANE, so alternative (non-MANE) sites are out-of-distribution for it. Evaluated there, the first M1-S blend actually scored below the base model — Ensembl-alt PR-AUC 0.704 vs base 0.749 — a genuine OOD regression. The v2 logit-blend fixed the regression (0.775), but 0.775 is still far from usable: a MANE-only model, however well blended, cannot recognize sites its training annotation never contained.

That motivated training a model directly on the broader Ensembl annotation — M2-S. The full narrative is in ood_generalization.md.


Current results (v4)

Model m2s_v4_cleanannot — same architecture as M1-S, trained on Ensembl labels (Workflow Stage 5) and evaluated with the dedicated alternative-site protocol (Stage 6).

Alternative sites (Ensembl ∖ MANE; 70,923 alt sites / 14,724 genes, paralog-cleaned):

Base (OpenSpliceAI) M2-S (v4)
Alt-site macro PR-AUC 0.911 0.990
Donor / acceptor PR-AUC 0.920 / 0.902 0.993 / 0.987
Donor recall 0.174 0.904
FN reduction vs base 88.2%

The base model finds ~17% of alternative sites; M2-S finds ~90% — a 5.3× recall gain — while holding precision roughly level. On the overall Ensembl test set at the F1-optimal operating point, M2-S runs precision 0.97 / recall 0.94 / F1 0.956. Validation macro PR-AUC was 0.953 (epoch 6).

Alternative-site recovery is a discovery-mode tradeoff

Going from 17% to 90% recall necessarily admits more positives. At a fixed argmax threshold the overall false-positive count rises sharply — the model is deliberately operating in a high-recall discovery regime. Judge it by PR-AUC and by precision/recall at the F1-optimal point (above), not by argmax FP counts.

Cross-annotation check (GENCODE). The same effect holds on GENCODE ∖ MANE: M2-S reaches PR-AUC 0.907, and even M1-S v2 improves GENCODE-alt to 0.728 vs base 0.637 (+0.091) with false positives down 85.8% — evidence the gain generalizes beyond the Ensembl definition.

Modality contribution. As with the canonical models, junction is the dominant channel — removing it drops overall PR-AUC by 0.029, the largest single-modality effect (removing all multimodal channels: −0.053).


Version history

Version Alt-site PR-AUC Alt-site recall Notes
v1 0.967 ~59% first Ensembl-trained model
v2 0.9665 ~66% learned blend (α = 0.665); val macro PR-AUC 0.833
v4 (cleanannot) 0.990 ~90% current promoted model; FN −88%

Reconciling older numbers

Earlier docs report the v1/v2 alternative-site result two ways (recall ~59% vs ~66%) because one table predates the v2 retrain. Both are superseded by v4 — treat the v4 row above as authoritative and the earlier figures as historical context only.


Takeaways

  • Alternative-site recognition is the meta layer's highest-leverage result: recall from ~17% to ~90%, PR-AUC 0.911 → 0.990.
  • The win comes from training on the right annotation (Ensembl), not from a fancier architecture — M2-S shares M1-S's design. The architecture-search post-mortem (M2/architecture_and_inductive_bias_lessons.md) reached the same conclusion: leverage is upstream in features and labels, not in fusion.
  • Junction evidence again carries the multimodal signal — consistent with M1, and a useful contrast with M3, where junction is deliberately withheld as the prediction target.